WHAT IS CLAIMED IS:

1. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) a selective estrogen receptor modulator selected from the group consisting of Raloxifene, Tamoxifen, Toremifene, Arzoxifene (LY 353381), LY 335563 (Desmethylarzoxifene), LY 335124, LY 326315, CHF-4227, Lasofoxifene (CP-336,156), LY-2066948, LY-2120310, Ospemifene, Sivifene (A-007), TAS-108, Bazedoxifene acetate (TSE-424), Pipendoxifene (ERA-923), Afimoxifene, (Z)-4-hydroxytamoxifen, Clomiphene, Enclomiphene, Fispemifene, Acolbifene (EM-652·HCl, EM-1538), EM-652, EM-800, Droloxifene, Idoxifene, GW-5638, Iproxifen (TAT-59), GW-7603, Centchroman, Levormeloxifene, PSK-3471, BL-3040, SRI-16158, SRI-16137, Rad-1901, SERM 3471, HMR 3339, HMR 3656, CC 8490, and (+)-3-(4-Hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-4-(trifluoromethyl)-2H-chromen-7-ol and with (iii) a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol or salt of the foregoing compounds in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases selected from the group consisting of endometriosis, uterine fibroids, uterine leiomyomas, endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer, breast cancer, polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical

intraepithelial neoplasia and adenomyosis, comprising inhibiting ovarian hormonal secretion in a patient.

2. The use of claim 1 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

3. The use of claim 1 wherein said estrogen-related disease is endometriosis.

4. The use of claim 1 wherein said estrogen-related diseases are uterine fibroids or uterine leiomyomas.

5. The use of claim 1 wherein said estrogen-related diseases are endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer or breast cancer.

6. The use of claim 1 wherein said estrogen-related diseases are polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical intraepithelial neoplasia or adenomyosis.

7. The use of claim 1 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, and androst-5-ene-3β,17β-diol.

8. The use of claim 1 wherein the sex steroid precursor is dehydroepiandrosterone.

9. The use of claim 1 wherein said patient is a human.

10. The use of claim 1 wherein said selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538) and where said sex steroid precursor is dehydroepiandrosterone.

11. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

12. Use of (i) an LHRH agonist selected from the group consisting of leuprolide acetate, goserelin acetate, nafarelin, buserelin acetate, histrelin acetate, triptorelin acetate or pamoate, and deslorelin acetate or LHRH antagonist selected from the group consisting of abarelix, teverelix, cetrorelix acetate, ganirelix acetate, iturelix, acyline, degarelix, ornirelix, azaline B, ozarelix, LXT-101, elagolix, TAK-013, TAK-385, and T-98475 in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.